Rashid Ahmed Bux

Mr. Rashid Ahmed Bux


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MVMaria Vaida
Maria Vaida
JWJiawen Wu
Jiawen Wu
EHEyad Akram Himdiat
Eyad Akram Himdiat
JHJean-Francois Haince
Jean-Francois Haince
RBRashid Ahmed Bux
Rashid Ahmed Bux
WFW. Rand Ford
W. Rand Ford
Lung cancer remains the leading cause of cancer-related mortality worldwide, with early detection critical for improving survival rates, yet conventional methods like CT scans often yield high false-positive rates. This study introduces M-GNN, a graph neural network framework leveraging GraphSAGE, to enhance early lung cancer detection through metabolomics. We constructed a heterogeneous graph integrating metabolomics data from 800 plasma samples (586 cases, 214 controls) with demographic features and Human Metabolome Database annotations, employing GraphSAGE and GAT layers for inductive learning on 107 metabolites, pathways, and diseases. M-GNN achieved a test accuracy of 89% and an ROC-AUC of 0.92, with rapid convergence within 400 epochs and robust performance across ten random seeds; key predictors included age, height, choline, Valine, Betaine, and Fumaric Acid, reflecting smoking and metabolic dysregulation. This framework offers a scalable, interpretable tool for precision oncology, surpassing benchmarks by capturing complex biological interactions, though limitations like synthetic data biases and computational demands suggest future validation with real-world cohorts and optimization. M-GNN advances lung cancer screening, promising improved survival through early detection and personalized strategies.

22 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
VYVinith Yathindranath
Vinith Yathindranath
NSNura Safa
Nura Safa
BSBabu Sajesh
Babu Sajesh
KSKelly Schwinghamer
Kelly Schwinghamer
MVMagimairajan Issai Vanan
Magimairajan Issai Vanan
Donald MillerDonald Miller
Donald Miller
Spermidine/spermine N1-acetyltransferase 1 (SAT1) responsible for cell polyamine catabolism is overexpressed in glioblastoma multiforme (GB). Its role in tumor survival and promoting resistance towards radiation therapy has made it an interesting target for therapy. In this study, we prepared a lipid nanoparticle-based siRNA delivery system (LNP-siSAT1) to selectively knockdown (KD) SAT1 enzyme in a human glioblastoma cell line. The LNP-siSAT1 containing ionizable DODAP lipid was prepared following a microfluidics mixing method and the resulting nanoparticles had a hydrodynamic size of around 80 nm and a neutral surface charge. The LNP-siSAT1 effectively knocked down the SAT1 expression in U251, LN229, and 42MGBA GB cells, and other brain-relevant endothelial (hCMEC/D3), astrocyte (HA) and macrophage (ANA-1) cells at the mRNA and protein levels. SAT1 KD in U251 cells resulted in a 40% loss in cell viability. Furthermore, SAT1 KD in U251, LN229 and 42MGBA cells sensitized them towards radiation and chemotherapy treatments. In contrast, despite similar SAT1 KD in other brain-relevant cells no significant effect on cytotoxic response, either alone or in combination, was observed. A major roadblock for brain therapeutics is their ability to cross the highly restrictive blood–brain barrier (BBB) presented by the brain microcapillary endothelial cells. Here, we used the BBB circumventing approach to enhance the delivery of LNP-siSAT1 across a BBB cell culture model. A cadherin binding peptide (ADTC5) was used to transiently open the BBB tight junctions to promote paracellular diffusion of LNP-siSAT1. These results suggest LNP-siSAT1 may provide a safe and effective method for reducing SAT1 and sensitizing GB cells to radiation and chemotherapeutic agents.

Verified
Journal Article
Open access
PDF file
MVMaria Vaida
Maria Vaida
KAKamala Arumalla
Kamala Arumalla
PTPavan Kumar Tatikonda
Pavan Kumar Tatikonda
Bharadwaj PopuriBharadwaj Popuri
Bharadwaj Popuri
RBRashid Ahmed Bux
Rashid Ahmed Bux
WFW. Randolph Ford
W. Randolph Ford
Breast cancer remains a major public health concern, and early detection is crucial for improving survival rates. Metabolomics offers the potential to develop non-invasive screening and diagnostic tools based on metabolic biomarkers. However, the inherent complexity of metabolomic datasets and the high dimensionality of biomarkers complicates the identification of diagnostically relevant features, with multiple studies demonstrating limited consensus on the specific metabolites involved. Unlike previous studies that rely on singular feature selection techniques such as Partial Least Square (PLS) or LASSO regression, this research combines supervised and unsupervised machine learning methods with random sampling strategies, offering a more robust and interpretable approach to feature selection. This study aimed to identify a parsimonious and robust set of biomarkers for breast cancer diagnosis using metabolomics data. Plasma samples from 185 breast cancer patients and 53 controls (from the Cooperative Human Tissue Network, USA) were analyzed. This study also overcomes the common issue of dataset imbalance by using propensity score matching (PSM), which ensures reliable comparisons between cancer and control groups. We employed Univariate Naïve Bayes, L2-regularized Support Vector Classifier (SVC), Principal Component Analysis (PCA), and feature engineering techniques to refine and select the most informative features. Our best-performing feature set comprised 11 biomarkers, including 9 metabolites (SM(OH) C22:2, SM C18:0, C0, C3OH, C14:2OH, C16:2OH, LysoPC a C18:1, PC aa C36:0 and Asparagine), a metabolite ratio (Kynurenine-to-Tryptophan), and 1 demographic variable (Age), achieving an area under the ROC curve (AUC) of 98%. These results demonstrate the potential for a robust, cost-effective, and non-invasive breast cancer screening and diagnostic tool, offering significant clinical value for early detection and personalized patient management.

Verified
Journal Article
Open access
PDF file
KAKamala K. Arumalla
Kamala K. Arumalla
JHJean-Francois Haince
Jean-Francois Haince
RBRashid Ahmed Bux
Rashid Ahmed Bux
GHGUOYU HUANG
GUOYU HUANG
PTParamjit S Tappia
Paramjit S Tappia
MVMaria Vaida
Maria Vaida
Breast cancer is a global concern as a leading cause of death for women. Early and precise diagnosis can be vital in handling the disease efficiently. Breast cancer subtyping based on estrogen receptor (ER) status is crucial for determining prognosis and treatment. This study uses metabolomics data from plasma samples to detect metabolite biomarkers that could distinguish ER-positive from ER-negative breast cancers in a non-invasive manner. The dataset includes demographic information, ER status, and metabolite levels from 188 breast cancer patients and 73 healthy controls. Recursive Feature Elimination (RFE) with a Random Forest (RF) classifier identified an optimal subset of 30 features—29 biomarkers and age—that achieved the highest area under the curve (AUC). To address the class imbalance, Gaussian noise-based augmentation and Adaptive Synthetic Oversampling (ADASYN) were applied, ensuring balanced representation during training. Four machine learning (ML) algorithms—Random Forest, Support Vector Classifier (SVC), XGBoost, and Logistic Regression (LR)—were evaluated using grid search. The Random Forest classifier emerged as the top performer, achieving an AUC of 0.95 and an accuracy of 93%. These results suggest that ML has great promise for identifying specific metabolites linked to ER expression, paving the development of a novel analytical tool that can minimize current challenges in identifying ER status, and improve the precision of breast cancer subtyping.

Verified
Journal Article
Open access
PDF file
LZLun Zhang
Lun Zhang
JZJiamin Zheng
Jiamin Zheng
RBRashid Ahmed Bux
Rashid Ahmed Bux
JHJean-Francois Haince
Jean-Francois Haince
CTClaudia Torres-Calzada
Claudia Torres-Calzada
David Scott WishartDavid Scott Wishart
David Scott Wishart
Early detection of lung cancer significantly improves survival, yet current screening methods have limitations. This study aimed to identify a robust panel of plasma metabolites for early-stage non-small cell lung cancer (NSCLC) diagnosis using a large, clinically diverse patient cohort. A total of 680 archived plasma samples from biopsy-confirmed NSCLC patients and controls (including healthy individuals and patients with non-cancerous lung diseases) were analyzed using targeted, quantitative mass spectrometry-based metabolomics and used as the discovery cohort. An independent set of 216 plasma samples served as the validation cohort. Logistic regression (LR) models developed from the discovery set using ten metabolites achieved area under the receiver-operating characteristic curve (AUROC) values of 93.63%, 93.74%, and 93.91% for distinguishing all-stage, stage I–II, and stage I NSCLC patients from controls, respectively. Incorporating smoking history further improved model performance. The validation cohort confirmed the model’s robustness, demonstrating high sensitivity and specificity for early-stage detection. These results support the potential of metabolomic biomarkers as a minimally invasive, accurate tool for early NSCLC diagnosis. This approach may complement current screening methods, enabling earlier intervention and improved patient outcomes. Further studies are warranted to validate these findings in more diverse populations and real-world clinical settings.

17 September 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CBClémence Boullier
Clémence Boullier
FLFabien Lamaze
Fabien Lamaze
JHJean-Francois Haince
Jean-Francois Haince
RBRashid Ahmed Bux
Rashid Ahmed Bux
MOMichele Orain
Michele Orain
Philippe JoubertPhilippe Joubert
Philippe Joubert
Background/Objectives: Pulmonary neuroendocrine neoplasms (NENs) account for 20% of malignant lung tumors. Their management is challenging due to their diverse clinical features and aggressive nature. Currently, metabolomics offers a range of potential cancer biomarkers for diagnosis, monitoring tumor progression, and assessing therapeutic response. However, a specific metabolomic profile for early diagnosis of lung NENs has yet to be identified. This study aims to identify specific metabolomic profiles that can serve as biomarkers for early diagnosis of lung NENs. Methods: We measured 153 metabolites using liquid chromatography combined with mass spectrometry (LC-MS) in the plasma of 120 NEN patients and compared them with those of 71 healthy individuals. Additionally, we compared these profiles with those of 466 patients with non-small-cell lung cancers (NSCLCs) to ensure clinical relevance. Results: We identified 21 metabolites with consistently altered plasma concentrations in NENs. Compared to healthy controls, 18 metabolites were specific to carcinoid tumors, 5 to small-cell lung carcinomas (SCLCs), and 10 to large-cell neuroendocrine carcinomas (LCNECs). These findings revealed alterations in various metabolic pathways, such as fatty acid biosynthesis and beta-oxidation, the Warburg effect, and the citric acid cycle. Conclusions: Our study identified biomarker metabolites in the plasma of patients with each subtype of lung NENs and demonstrated significant alterations in several metabolic pathways. These metabolomic profiles could potentially serve as biomarkers for early diagnosis and better management of lung NENs.